Novo Nordisk Opens Oral Wegovy in Mexico as Buyback and Raised Guidance Round Out the Story
Published on 11/11/2026 at 06:31 | Editorial boerse-global.de
Novo Nordisk began rolling out its Wegovy pill in Mexico on Monday, bringing a once-daily oral alternative to the weekly injection into a market where the company sees 7.5 million potential patients — fewer than 1% of whom are currently treated. The Mexican approval, granted by regulator COFEPRIS in August, makes the country the first in Latin America to clear this oral form for weight management.
Distribution will widen over the coming weeks toward nearly 10,000 points of sale. Each tablet carries 25 mg of semaglutide and is taken daily, and the drug is aimed at adults with obesity or with excess weight plus at least one weight-related condition. Prescription and medical supervision remain mandatory. Pricing will vary by dose and outlet and is expected to sit close to the injectable product — Novo is not dangling a cheaper option at launch. The selling point is the delivery method itself.
What the OASIS-4 Data Show
The clinical case rests in part on OASIS-4, which tracked 205 participants on semaglutide and 102 on placebo for 64 weeks. All were adults with overweight or obesity and no diabetes — the group that matters for judging the results. Average weight loss reached 13.6% on semaglutide versus 2.2% on placebo, with an estimated 16.6% reduction for those who continued treatment without other weight-loss therapies.
Tolerability will matter as much as efficacy over the long haul. Gastrointestinal side effects — nausea, diarrhoea, vomiting, constipation and abdominal pain — hit 74% of semaglutide participants against 42.2% on placebo, which puts a premium on physician follow-up if patients are to stay on the drug.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Buyback and a Brighter Outlook
Alongside the launch, Novo disclosed the purchase of 890,000 B shares for DKK 243.6 million, executed between 3 and 6 November under its buyback programme. The repurchase came days after the company lifted its full-year guidance on 4 November for adjusted revenue and adjusted operating profit growth, now seen at between -2% and +2% at constant exchange rates for 2026, up from a prior range of -6% to 0%. The new band still leaves room for either a decline or an advance.
Third-quarter 2026 revenue came in at DKK 79.2 billion, with adjusted operating profit of DKK 31.7 billion. The Wegovy tablet contributed DKK 5.39 billion in the quarter; by period-end it had launched in the US, the United Arab Emirates, the UK and Germany, with four more countries added afterwards.
Australia Clears Four Strengths
Australia's Therapeutic Goods Administration approved the pill in four strengths on 3 November, covering weight management and reduction of cardiovascular risk in eligible adults, with Novo expecting availability before year-end. On the personnel front, Luigi La Corte — then finance chief at Galderma — was named on 4 November to succeed Karsten Munk Knudsen, who is due to leave at the end of the year.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
For investors, the Mexican debut adds a growth lever only if easier administration draws more patients into supervised care and keeps them there. The breadth of the pharmacy network and the durability of treatment are the tests that will decide how much the launch actually contributes.
Ad
Novo Nordisk Stock: New Analysis - 11 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
